Analyst Ratings For Atara Biotherapeutics (NASDAQ:ATRA)
Today, Canaccord Genuity reiterated its Buy rating on Atara Biotherapeutics (NASDAQ:ATRA) with a price target of $70.00.
Some recent analyst ratings include
- 1/19/2018-Canaccord Genuity Reiterated Rating of Buy .
- 1/3/2018-Citigroup Upgrade from a “Sell ” rating to a ” Neutral” rating.
- 10/6/2017-Goldman Sachs Group Reiterated Rating of Neutral .
- 10/5/2017-Jefferies Group Reiterated Rating of Buy.
- 6/26/2017-William Blair Reiterated Rating of Outperform.
- 7/9/2016-JMP Securities Reiterated Rating of Buy.
Recent Insider Trading Activity For Atara Biotherapeutics (NASDAQ:ATRA)
Atara Biotherapeutics (NASDAQ:ATRA) has insider ownership of 16.20% and institutional ownership of 69.67%.
- On 12/29/2018 John Mcgrath, CFO, sold 32,000 with an average share price of $20.00 per share and the total transaction amounting to $640,000.00.
- On 12/28/2018 Isaac E Ciechanover, CEO, sold 2,200 with an average share price of $15.15 per share and the total transaction amounting to $33,330.00.
- On 1/16/2018 Isaac E Ciechanover, CEO, sold 600 with an average share price of $30.38 per share and the total transaction amounting to $18,228.00.
- On 1/12/2018 Isaac E Ciechanover, CEO, sold 28,700 with an average share price of $21.39 per share and the total transaction amounting to $613,893.00.
- On 1/12/2018 John Mcgrath, CFO, sold 37,000 with an average share price of $24.35 per share and the total transaction amounting to $900,950.00.
- On 1/10/2018 Isaac E Ciechanover, CEO, sold 8,600 with an average share price of $19.99 per share and the total transaction amounting to $171,914.00.
- On 12/29/2017 Isaac E Ciechanover, CEO, sold 22,200 with an average share price of $18.29 per share and the total transaction amounting to $406,038.00.
Recent Trading Activity for Atara Biotherapeutics (NASDAQ:ATRA)
Shares of Atara Biotherapeutics closed the previous trading session at 28.82 up +1.33 4.82% with 29.450000762939453 shares trading hands.